Maxime Courtehoux
Research Subjects
Maxime Courtehoux has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Alain Manrique
Department of Nuclear Medicine, Normandie Univ, UNICAEN, CHU de Caen Normandie, Caen, France
1 shared publication - Anne-Claire Dupont
Unité de Radiopharmacie, CHRU de Tours, Tours, France.
1 shared publication - Diane Darsin-Bettinger
Nuclear Medicine Department, CHU Orleans, 45100 Orléans, France
1 shared publication - Gilles Metrard
Nuclear Medicine Department, Orléans University Hospital, Orléans, France
1 shared publication - Guillaume Domain
Cardiology Department, CHU Orleans, 45100 Orléans, France
1 shared publication - Jonathan Vigne
Department of Nuclear Medicine, CHU de Caen Normandie, Normandie Université, UNICAEN, 14000 Caen, France
1 shared publication
Latest Publications
- Open Access
- 9 March 2025
- Published by MDPI AG in Pharmaceuticals
- Vol. 18 (3) , 387
Gallium-Labeled PET Radiopharmaceuticals in Cardiovascular Disease
Gallium-labeled positron emission tomography (PET) probes targeting activated fibroblasts or somatostatin receptor expression are frequently used for varying applications in oncology. With the widespread availability of 68Ge/68Ga generators and cold kits, 68Ga tracers have become a main tool in molecular imaging. These tracers, such as [68Ga]Ga-DOTA-TATE, [68Ga]Ga-FAPI, and [68Ga]Ga-pentixafor, allow targeted imaging of the key pathological processes, including inflammation, fibrosis, and necrosis. This review highlights their potential in conditions like myocardial infarction, cardiac sarcoidosis, myocarditis, and other cardiomyopathies. Clinical and preclinical studies underscore their utility in visualizing active disease processes, predicting outcomes, and guiding therapeutic strategies. However, challenges remain, including the need for standardization, larger clinical trials, and integration into routine practice. These advancements position 68Ga-based PET as a promising modality for enhancing diagnostic precision and personalized treatment in cardiovascular disease.
- 9 March 2025
- Published by MDPI AG in Pharmaceuticals
- Vol. 18 (3) , 387
Open AccessGallium-Labeled PET Radiopharmaceuticals in Cardiovascular Disease
Gallium-labeled positron emission tomography (PET) probes targeting activated fibroblasts or somatostatin receptor expression are frequently used for varying applications in oncology. With the widespread availability of 68Ge/68Ga generators and cold kits, 68Ga tracers have become a main tool in molecular imaging. These tracers, such as [68Ga]Ga-DOTA-TATE, [68Ga]Ga-FAPI, and [68Ga]Ga-pentixafor, allow targeted imaging of the key pathological processes, including inflammation, fibrosis, and necrosis. This review highlights their potential in conditions like myocardial infarction, cardiac sarcoidosis, myocarditis, and other cardiomyopathies. Clinical and preclinical studies underscore their utility in visualizing active disease processes, predicting outcomes, and guiding therapeutic strategies. However, challenges remain, including the need for standardization, larger clinical trials, and integration into routine practice. These advancements position 68Ga-based PET as a promising modality for enhancing diagnostic precision and personalized treatment in cardiovascular disease.